A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Desvenlafaxine Succinate in the Treatment of Major Depressive Disorder
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study evaluated the efficacy and safety of desvenlafaxine succinate extended-release in major depressive disorder (MDD). METHOD: Adult outpatients with DSM-IV-defined MDD were randomly assigned to desvenlafaxine 100 mg/day (N = 114), 200 mg/day (N = 116), or 400 mg/day (N = 113) or placebo (N = 118) for 8 weeks. Efficacy variables included change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D(17), the primary efficacy measure), Clinical Global Impressions-Improvement scale (CGI-I), Montgomery-Asberg Depression Rating Scale, Clinical Global Impressions-Severity of Illness scale (CGI-S), rates of response (> or = 50% decrease from baseline HAM-D(17) score) and remission (HAM-D(17) score < or =7), and Visual Analog Scale-Pain Intensity overall score. The study was conducted from November 2003 to November 2004. RESULTS: At the final on-therapy evaluation, the mean HAM-D(17) scores for desvenlafaxine 100 mg/day (12.75) and 400 mg/day (12.50) were significantly lower than for placebo (15.31; p = .0038 and p = .0023, respectively); for desvenlafaxine 200 mg/day, the mean score was 13.31 (p = .0764). CGI-I and Montgomery-Asberg Depression Rating Scale results were significant for all groups; CGI-S results were significant with 100 mg/day and 400 mg/day. Response rates were significantly greater for desven-lafaxine 100 mg/day (51%) and 400 mg/day (48%) versus placebo (35%; p = .017 and p = .046, respectively); the response rate for desvenlafaxine 200 mg/day was 45% (p = .142). Remission rates were significantly greater for desvenlafaxine 400 mg/day (32%) versus placebo (19%; p = .035); remission rates were 30% for desvenlafaxine 100 mg/day (p = .093) and 28% for desvenlafaxine 200 mg/day (p = .126). Visual Analog Scale-Pain Intensity results were significant for desvenlafaxine 100 mg/day versus placebo (p = .002), but not for the higher doses. The most commonly reported adverse events were nausea, insomnia, somnolence, dry mouth, dizziness, sweating, nervousness, anorexia, constipation, asthenia, and abnormal ejaculation/orgasm. CONCLUSIONS: Desvenlafaxine is effective and well tolerated in the short-term treatment of MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.629 · Cited by 2,695 · cited 1×
“Nausea 10 (8) 41 (35) 36 (31) 47 (41) Insomnia 10 (8) 26 (22) 21 (18) 35 (30) Somnolence 10 (8) 24 (20) 25 (22) 30 (26) Dry mouth 12 (10) 20 (17) 22 (19) 29 (25) Sweating 4 (3) 12 (10) 19 (16) 24 (21) Dizziness 7 (6) 20 (17) 18 (16) 22 (19) Nervousness 5 (4) 6 (5) 10 (9) 17 (15) Anorexia 3 (3) 14 (12) 14 (12) 16 (14)…”
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 1×
“Nausea 10 (8) 41 (35) 36 (31) 47 (41) Insomnia 10 (8) 26 (22) 21 (18) 35 (30) Somnolence 10 (8) 24 (20) 25 (22) 30 (26) Dry mouth 12 (10) 20 (17) 22 (19) 29 (25) Sweating 4 (3) 12 (10) 19 (16) 24 (21) Dizziness 7 (6) 20 (17) 18 (16) 22 (19) Nervousness 5 (4) 6 (5) 10 (9) 17 (15) Anorexia 3 (3) 14 (12) 14 (12) 16 (14)…”
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Cited by
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269
Rickels, K., Montgomery, S. A., Tourian, K. A., Guelfi, J. D., Pitrosky, B., Padmanabhan, S. K., Germain, J.-M., Leurent, C., & Brisard, C. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c94c4d · Cited by 33
Montgomery, S. A., Fava, M., Padmanabhan, S. K., J. Guico-Pabia, C., & Tourian, K. A. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832fbb5a · Cited by 27
Lee, S.-H., Jeon, S. W., Shin, C., Pae, C.-U., Patkar, A. A., Masand, P. S., An, H., & Han, C. (2022) · Psychiatry Investigation · doi:10.30773/pi.2021.0368 · Cited by 12
Metadata
- Authors
- DeMartinis, N. A., Yeung, P. P., Entsuah, R., & Manley, A. L.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-05-15
- Volume
- 68
- Issue
- 05
- Pages
- 677-688
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2044018276
- Cited by
- 108
- References
- 4
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Desvenlafaxine Succinate in the Treatment of Major Depressive Disorder. https://app.cochat.ai/papers/10.4088/jcp.v68n0504
- The paper
- DeMartinis, N. A., Yeung, P. P., Entsuah, R., & Manley, A. L. (2007). A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Desvenlafaxine Succinate in the Treatment of Major Depressive Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v68n0504
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.